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An intact C-terminal end of albumin is required
for its long half-life in humans
Jeannette Nilsen1,2, Esben Trabjerg3, Algirdas Grevys1,2, Claudia Azevedo4, Stephen O. Brennan5,
Maria Stensland1,6, John Wilson 7, Kine Marita Knudsen Sand1,8, Malin Bern1,2, Bjørn Dalhus9,
Derry C. Roopenian7, Inger Sandlie1,8, Kasper Dyrberg Rand 10 & Jan Terje Andersen1,2✉
Albumin has an average plasma half-life of three weeks and is thus an attractive carrier to
improve the pharmacokinetics of fused therapeutics. The half-life is regulated by FcRn, a
cellular receptor that protects against intracellular degradation. To tailor-design the ther-
apeutic use of albumin, it is crucial to understand how structural alterations in albumin affect
FcRn binding and transport properties. In the blood, the last C-terminal residue (L585) of
albumin may be enzymatically cleaved. Here we demonstrate that removal of the L585
residue causes structural stabilization in regions of the principal FcRn binding domain and
reduces receptor binding. In line with this, a short half-life of only 3.5 days was measured for
cleaved albumin lacking L585 in a patient with acute pancreatitis. Thus, we reveal the
structural requirement of an intact C-terminal end of albumin for a long plasma half-life,
which has implications for design of albumin-based therapeutics.
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A lbumin acts as a versatile carrier of a wide range of sub-stances, such as fatty acids, steroids, thyroid hormones,and metals, and plays an important role in stabilizing the
extracellular fluid volume1. It is expressed by hepatocytes in the
liver as a single polypeptide of 585 amino acids, and consists of
67% α-helices, which fold into three homologous domains
denoted DI, DII, and DIII2,3. In the blood, it is the most abundant
protein (40 g/L), with a long plasma half-life of ~3 weeks in
humans1.
Albumin is of interest for the pharmaceutical industry because
of its ability to bind a wide range of small chemical drugs that
consequently affect their pharmacokinetics4. In addition, it is
increasingly utilized to improve the pharmacokinetics of short-
lived bioactive therapeutic peptides and proteins by genetic fusion
of such molecules to the N- or C-terminal end5. Two human
serum albumin (HSA) fused drugs have been approved for clinical
use; Tanzeum® and Idelvion®, which contain glucagon-like peptide
1 and recombinant coagulation factor IX, respectively. Both drugs
are genetically fused to the N-terminal of HSA, which prolongs
the half-life from 2min to 5 days for the peptide and from 22 h to
102 h for the coagulation factor, giving rise to better dosing
options for patients with type II diabetes and hemophilia B6,7.
The biological mechanism responsible for its persistence in
blood was revealed when Chaudhury et al.8 discovered that
albumin binds a cellular receptor, namely the neonatal Fc
receptor (FcRn). At the time, FcRn was already known to bind
antibodies of the IgG class and play a key role in controlling their
long serum half-life9–11. It was then discovered that FcRn-
deficient mice not only had dramatically reduced serum levels of
IgG but also less than half of normal albumin levels. Furthermore,
the half-lives of both proteins were considerably shortened in
such mice compared with wild-type (WT) mice8. The cellular
mechanism responsible has been studied by live-cell imaging
tracking co-transport of IgG and FcRn in human endothelial cells,
which shows that FcRn is predominantly found within acidic
endosomes, where it binds IgG that has entered the cell by fluid-
phase pinocytosis. Binding is only initiated at slightly acidic pH
(5.0–6.5) and when the FcRn–IgG complex is recycled back to the
cell surface membrane, exocytosis, and exposure to the physio-
logical pH (7.4) of the blood triggers dissociation and release of
IgG back into the circulation12–17. Thus, this binding-and-release
mechanism is based on strict pH-dependent binding between
FcRn and IgG. Similarly, FcRn binds albumin at slightly acidic
pH and not at neutral pH, and recent reports support that
albumin is recycled via the same route, independently of IgG18–
21.
FcRn belongs to a family of major histocompatibility class I-
related molecules, and consists of a unique heavy chain (HC),
with three extracellular domains (α1, α2, and α3) in non-covalent
association with β2-microglobulin (β2m)22–24. Albumin binds to a
region on FcRn that is distal from the IgG-binding site, and site-
directed mutagenesis studies as well as X-ray crystallographic
studies have provided in-depth insight into how FcRn binds
albumin in a pH-dependent fashion8,25–27. At slightly acidic pH,
H166 within the α2-domain of the HC of FcRn stabilizes a loop in
the α1-domain through intramolecular interactions with E54 and
Y60, which are not formed at neutral pH25,28–30. This makes
conserved tryptophan residues (W53 and W59) in the loop
available for binding to albumin29. DIII of HSA contains the
main binding site for human FcRn (hFcRn), where three con-
served histidine residues (H464, H510, and H535) sustain
hydrophobic pockets within DIII in a conformation that pro-
motes insertion of W53 and W59 of hFcRn at slightly acidic
pH26,30–32. More recently, we and others demonstrated that DI of
HSA modulates the interaction via two surface-exposed loops that
form direct contacts with the receptor26,31,33.
The discovery that FcRn is a key controller of albumin
homeostasis opens new possibilities for rational design of
albumin-based therapeutics, such as to tailor the half-life of drugs
by engineering the interaction. One of the first examples of such
engineering is an HSA variant with a single-point mutation in
DIII (K573P), which improves binding to hFcRn by more than
tenfold and extends the plasma half-life from 5.4 to 8.8 days in
cynomolgus monkeys34. The variant is one of a panel of engi-
neered HSA variants with altered pharmacokinetics that together
constitute the so-called Veltis® technology.
To further optimize the therapeutic use of albumin, it is crucial
to fully understand how structural alterations and fusion to
albumin affects its ability to bind and to be transported by FcRn.
In this study, we demonstrate that truncations and amino acid
substitutions in the last C-terminal α-helix of albumin strongly
reduce binding to the receptor, where even removal of the last
residue (L585) has a negative effect on FcRn binding. HDX-MS
analysis shows that deletion of L585 causes structural stabilization
in regions of the C-terminal DIII that otherwise require flexibility
to allow optimal binding. Furthermore, lack of L585 resulted in
reduced rescue from intracellular degradation and a shorter
serum half-life in hFcRn transgenic mice. In agreement, we found
that the truncated variant was quickly eliminated from the blood
of a patient diagnosed with acute gallstone-induced pancreatitis
and measured a half-life of 3.5 days only. Moreover, exposure to
carboxypeptidase A, an enzyme found at elevated levels in plasma
of individuals with pancreatitis, resulted in cleavage of L585 from
the C-terminal end of HSA, also in the approved drug Tanzeum®,
and consequently reduced hFcRn binding. Thus, we provide
evidence for the requirement of a structurally intact C-terminal
end of HSA to maintain optimal binding to hFcRn and a long
plasma half-life, which should guide design of the next generation
of albumin-based therapeutics.
Results
C-terminal modified HSA variants show reduced FcRn bind-
ing. The three homologous domains (DI, DII, and DIII) of albu-
min are connected by flexible loops and form a heart-shaped
structure, where DIII harbors the principal binding site for
FcRn2,3,26,30. Interestingly, we have observed that introducing
mutations in the last C-terminal helix of DIII affects binding to
hFcRn, which is not easily explained by available co-crystal
structural models26,31,34. We became aware of four naturally
occurring HSA variants with alterations in this C-terminal region,
which are named Bazzano, Catania, Rugby Park, and Venezia35–38.
Bazzano and Catania are products of a single-nucleotide deletion
and a subsequent frameshift, resulting in truncated variants
lacking three amino acids and with replacement of the last 19 or
6 C-terminal amino acid residues, respectively36,38 (Fig. 1a).
Rugby Park and Venezia are truncated by seven amino acids, and
have their C-terminal ends altered from position 572, due to a
splice error in intron 13 (Rugby park) or a 30-bp deletion and a 5-
bp insertion resulting in skipping of exon 14 (Venezia)35–37
(Fig. 1a).
We produced recombinant versions of the variants and
observed only minor differences in expression levels in compar-
ison with WT HSA (Fig. 1b, c). To measure receptor binding,
surface plasmon resonance (SPR) measurements were conducted
by immobilizing the HSA variants followed by injecting titrated
amounts of monomeric hFcRn at pH 5.5. Dissociation constants
(KD) were calculated by fitting the sensorgrams to a simple 1:1
Langmuir binding model or a steady- state affinity-binding
model. All four variants bound the receptor less well than the
WT, where Catania and Venezia showed a 6.6- and 7.6-fold
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decrease in affinity, respectively, while Bazzano and Rugby Park
bound with 9–10-fold weaker affinity (Fig. 1d–h, Table 1).
As an attempt to explain the effects of the naturally occurring
C-terminal alterations on receptor binding, we scrutinized a co-
crystal structural model of WT HSA in complex with hFcRn26
(Fig. 1i). None of the residues of the last C-terminal α-helix of
HSA contact the receptor, but several of them form intramole-
cular interactions with the second last α-helix (Fig. 1j). Both α-
helices are part of the hydrophobic pocket that accommodates
W53 of FcRn, where the second last α-helix contains residues
(e.g., F551) that form hydrophobic interactions with the
tryptophan26. Thus, truncating and substituting amino acid
residues of the last C-terminal α-helix, as in the mutated variants,
probably disrupt some of the helix–helix interactions and
consequently the binding pocket, resulting in the negative effect
on hFcRn binding.
L585 is required for optimal FcRn binding. Survey of albumin
sequences from 20 species indicates that all lack the C-terminal
L585 found in albumin from orangutan, chimpanzee, and human
(Fig. 2a). Moreover, clinical data demonstrate that 4–15% of
circulating albumin in humans also lack this residue39,40. To
address the effect of loss of L585, we expressed a truncated
recombinant version of HSA (L585X) (Fig. 2b). Circular
dichroism (CD) analysis at 25 °C and pH 5.5 showed very similar
ellipticity spectra as that of the WT (Fig. 2c). Binding to hFcRn at
pH 5.5 and pH 7.4 was first compared by ELISA, where the
receptor was captured onto a mutated hIgG1 variant that binds
strongly to FcRn at both pH conditions41. The HSA variants were
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Fig. 1 Genetic HSA variants with modified C-terminal ends show reduced FcRn binding. a An overview of the C-terminal sequences of genetic HSA
variants. b A 12% SDS-PAGE gel stained with Coomassie Blue showing 2 μg of purified recombinant WT HSA and genetic variants. The gel was cropped
and the full-length gel is shown in Supplementary Fig. 1. c Relative expression levels of WT HSA and genetic variants by transiently transfected HEK293E
cells. Protein secreted into the growth medium was quantified by ELISA, and the values represent the mean ± s.d. of four replicates. d SPR sensorgrams
showing binding of titrated amounts (0, 0.0625, 0.125, 0.25, 0.5, 1, 2, 4, 8, and 16 μM) of monomeric hFcRn injected over immobilized (~200 RU) WT HSA
at pH 5.5 (—) and the fit of the data to the 1:1 binding model (·····). Injections were performed at 25 °C, and the flow rate was 40 μl/min. e–h SPR
sensorgrams showing binding of titrated amounts (0, 0.625, 1.25, 2.5, 5, 10, 20, 40, and 80 μM) of monomeric hFcRn injected over immobilized (~500 RU)
(e) Bazzano, (f) Catania, (g) Rugby Park, and (h) Venezia at pH 5.5. Injections were performed at 25 °C, and the flow rate was 10 μl/min. (i) An illustration
of the co-crystal structure of WT HSA in complex with hFcRn. DI, DII, and DIII of HSA are colored in pink, wheat, and light blue, respectively. The three
domains, α1, α2, and α3, of the HC of hFcRn are shown in light green and the β2m subunit in gray. j A close-up of the two last α-helices of the C-terminal
end of HSA. The figures were made using PyMOL with the crystallographic data of WT HSA-hFcRn (PDB ID 4N0F)26.
Table 1 SPR-derived kinetics for binding of HSA variants
to hFcRn.
HSA
varianta
ka (104 M−1
s−1)
kd (10−2
s−1)
KDb (μM) KDc (μM)
WT 4.8 3.3 0.7 1.1
L585X 1.5 5.6 3.7 5.3
Bazzano NAd NA NA 10.0
Catania NA NA NA 7.3
Rugby Park NA NA NA 11.3
Venezia NA NA NA 8.4
aThe HSA variants were immobilized on CM5 chips and serial dilutions of hFcRn were injected
at pH 5.5.
bThe kinetic rate constants were obtained using a simple first-order (1:1) Langmuir bimolecular
interaction model.
cThe steady state affinity constant was obtained using an equilibrium (Req) binding model.
dNA, not acquired due to fast kinetics.
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then added and subsequently detected using polyclonal anti-HSA
from goat. Importantly, the detection antibody cannot bind via its
Fc to FcRn, as the IgG-binding site is already occupied when
added. Moreover, as the binding sites for IgG and albumin are
located at opposite sides of the receptor, the albumin-binding site
should be readily available. The result showed weaker binding of
the truncated variant compared with the WT at pH 5.5, while
binding of neither of the two was detected at pH 7.4 (Fig. 2d;
Supplementary Fig. 2a). We then extended the analysis to SPR,
where L585X was immobilized, and titrated amounts of mono-
meric hFcRn were injected at pH 5.5. Fitting the binding curve to
a 1:1 Langmuir binding model revealed a 5.3-fold reduction in
binding affinity, as a result of slower on-rate and faster off-rate,
for L585X compared with the full-length (Fig. 2e, Table 1). As
expected, no binding response was obtained when hFcRn was
injected at pH 7.4 (Supplementary Fig. 2b, c). Thus, removal of
the last C-terminal amino acid residue of HSA reduces binding to
hFcRn.
Deletion of L585 causes structural stabilization in DIII. As the
HSA-hFcRn co-crystal structure does not directly explain the
effect of removing L585, we studied the structural dynamics of
HSA with and without the C-terminal leucine using hydrogen/
deuterium exchange mass spectrometry (HDX-MS) at pH 5.5.
The rate at which backbone amides exchange their protons with
deuterium from solvent provides information about the con-
formational dynamics of proteins, as the rate of exchange of
backbone amides is primarily determined by the stability of local
hydrogen bonding42–44. The exchange rate can vary up to seven
orders of magnitude, when comparing a backbone amide in a
heavily structured region, such as in stable α-helices and β-
strands, to a backbone amide in less structured or disordered
regions (non-hydrogen bonded)43,45. Briefly, HDX was initiated
by diluting WT HSA or L585X into deuterated buffer. The
exchange reaction was stopped at various time points from 15 s
up to 2960 min (i.e., sampled across a time range of
approximately four orders of magnitude) by lowering the tem-
perature and pH. The quenched samples were digested by pepsin,
before the mass of the resulting peptides were determined by
liquid chromatography–mass spectrometry (LC–MS). Deuterium
incorporation for 77 peptides was followed for both the WT and
the truncated variant, covering 91% of the sequence (Supple-
mentary Figs. 3 and 4). Most peptide segments of HSA did not
display a difference in HDX between WT and L585X (Fig. 3e;
Supplementary Fig. 3). Also, no difference was observed for the
peptides corresponding to the last part of the C-terminal α-helix,
when correcting for the difference in the “experimental maxi-
mally” labeled samples (Fig. 3a). However, the HDX differed in
three other regions in DIII; residues 409–420 (Fig. 3b), 496–506
(Fig. 3c), and 530–550 (Fig. 3d), which are spatially in close
proximity to the C-terminal end in crystal structures of HSA
alone as well as when in complex with hFcRn (Fig. 3f, g). The
significance of these reductions in HDX was further supported in
the data from several overlapping peptides comprising these
regions of DIII (Supplementary Fig. 3). Interestingly, for all three
identified regions, the rate of HDX was slower for L585X, which
suggests that these regions are less dynamic in the truncated
variant. Thus, deletion of L585 causes local structural stabilization
in distinct regions of DIII.
HSA lacking L585 is more rapidly degraded. To study the
consequence of lack of L585 on FcRn-mediated recycling, we used
the newly developed human endothelial cell-based recycling assay
(HERA)20. Briefly, human microvascular endothelial cells
(HMEC1) that overexpress hFcRn were grown in wells until
95–100% confluency. The cells were starved for 1 h, before equal
amounts of WT HSA or L585X were added and incubated for 4 h
to allow uptake. The cells were washed, and fresh pH 7.4 buffer
was added. After another 4 h incubation, the amount of HSA
released from the cells was quantified using ELISA, which
revealed that only half the amount of the truncated variant was
recycled compared with full-length HSA (Fig. 4a).
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Fig. 2 Removal of L585 from HSA causes reduced hFcRn binding. a An alignment of the last 14 or 15 amino acid residues of the C-terminal α-helix of
multiple albumin species. b A 12% SDS-PAGE gel stained with Coomassie Blue showing 2 μg of purified recombinant WT HSA and L585X. c CD spectra of
WT HSA and L585X obtained at 20 °C and pH 5.5. MRE mean residual ellipticity. d ELISA showing binding of equal amounts (225 nM) of WT HSA and
L585X to hFcRn at pH 5.5. e SPR sensorgrams showing binding of titrated amounts (0, 0.0625, 0.125, 0.25, 0.5, 1, 2, 4, 8, 16, and 32 μM) of monomeric
hFcRn injected over immobilized (~300 RU) L585X at pH 5.5 (—) and the fit of the data to the 1:1 binding model (·····). Injections were performed at 25 °C
and the flow rate was 40 μl/min.
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complex (PDB ID 4N0F)26.
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Next, we measured the serum half-life of HSA with and
without L585 in two humanized mouse models, the so-called
Tg32 and Tg32-Alb−/− mouse strains46,47. While both strains
express hFcRn instead of the mouse receptor, the latter also lacks
expression of mouse albumin. In the albumin knockout mice
(Tg32-Alb−/−), a serum half-life of about 14 days was measured
for L585X as compared with 18 days for the WT (Fig. 4b). In the
presence of high levels of endogenous albumin (Tg32), the
truncated variant was eliminated even more rapidly relative to
full-length HSA, showing 1.7-fold shorter serum half-life
(decreased from 2.7 to 1.6 days) (Fig. 4c). Notably, both variants
showed monophasic log-linear decay curves, supporting the lack
of immunogenicity and of an antibody response, even in the
albumin deficient mice. The transgenic mice used have low levels
of endogenous IgG due to weak binding affinity between hFcRn
and mouse IgG8,48–50. However, engineered HSA variants
injected into hFcRn transgenic mice have previously been shown
to elicit antibody responses and cause increased clearance31.
Thus, C-terminal truncation leads to less efficient cellular
recycling and reduced serum half-life as a result of altered FcRn-
binding kinetics. HSA lacking L585, which binds hFcRn with
fivefold weaker affinity due to a slower on-rate and a faster off-
rate, is thus less likely to bind the receptor in the endosomes,
especially in the presence of large amounts of competing
endogenous albumin, and instead follow the default pathway to
the lysosomes.
Truncated HSA lacking L585 has a short half-life in humans.
Patients with pancreatitis have elevated pancreatic protease
activity in the circulation and as a result, the level of HSA lacking
L585 may increase dramatically39,40. We collected six blood
samples from a patient with acute gallstone induced pancreatitis
over a time period of 104 h, starting at the time the patient was
admitted to the hospital. To monitor the condition, we measured
the plasma activity of amylase and lipase (Fig. 5a), which are
commonly used diagnostic markers of pancreatitis51. Plasma
samples taken the first day showed markedly elevated activity of
both amylase (974–1023 U/I) and lipase (7880–7926 U/I), which
had decreased substantially by the 30 h blood sample (291 U/I
and 714 U/I, respectively), supporting that the pancreas was
recovering. Over the 104 h time period, the total serum albumin
concentration decreased slightly from 40.9 g/L to 35.9 g/L (Sup-
plementary Fig. 5a). The mass and heterogeneity of purified HSA
were assessed using LC–ESI–MS, which showed that a con-
siderable amount had a truncated C-terminal (Fig. 5b; Supple-
mentary Fig. 5b). The level of L585X increased during the first
2.2 h, which is when the level peaked at 60% of the total HSA.
Following the initial rise in concentration, the level declined over
the next 102 h, from which a half-life of only 3.5 days was cal-
culated (Fig. 5b). Moreover, we isolated truncated HSA from a
patient with 100% L585X, while full-length HSA was isolated
from a healthy individual in which L585X accounted for ~3% of
the total albumin (Supplementary Fig. 5c). As measured for the
recombinant version, plasma-derived L585X showed reduced
hFcRn binding compared with full-length HSA (Fig. 5c, d).
Carboxypeptidase A cleaves L585 of HSA. Carboxypeptidase A
(CPA), also referred to as CPA1, is a pancreatic protease that
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cleaves aromatic and aliphatic amino acid residues from the C-
terminal of proteins52. It is the enzyme predicted to cleave the C-
terminal L585 of HSA39,53. This is supported by increased serum
concentrations of CPA observed in parallel with elevated serum
levels of L585X in patients with pancreatitis54,55. We incubated
WT HSA with and without CPA purified from human pancreas
at 37 °C for 5 h followed by MS analysis, which confirmed that
exposure to the enzyme generated a product without L585
(Supplementary Table 1)53. The protocol was repeated with the
commercially available N-terminal HSA-drug fusion, Tanzeum®.
After exposure to CPA, more than 99% of the C-terminal pep-
tides detected were lacking L585, whereas the leucine was present
in the nonexposed sample (Supplementary Table 1). In addition,
we included the engineered variant, HSA K573P, which has
improved pH-dependent binding affinity for hFcRn and extended
half-life in nonhuman primates34. Incubation with CPA resulted
in complete removal of L585 from the C-terminal end of the
engineered variant (Supplementary Table 1). The effect of losing
L585 on hFcRn binding was then evaluated by ELISA, which
demonstrated weaker binding of the enzyme-exposed HSA and
fusion construct as compared with the nonexposed variants
(Fig. 6a; Supplementary Fig. 6). The same was observed for HSA
K573P, however, the cleaved version still bound more strongly
compared with non-cleaved WT HSA (Fig. 6a, b). Thus, CPA
cleaves the C-terminal L585 of HSA and causes reduced FcRn
binding.
Discussion
Albumin is the most abundant protein in blood and plays a key
role as carrier of primarily small hydrophobic and insoluble
molecules throughout the body. To take advantage of its long
plasma half-life and improve in vivo efficacy of drugs, one can
either target drugs to HSA via albumin-binding molecules, use
site-specific conjugation to C34 of HSA or genetically fuse pro-
teins of interest to the N- or C-terminal end of HSA5. In this
context, knowledge about how FcRn binds and controls the
plasma half-life and transport of albumin, as well as how struc-
tural alterations and fusion to albumin affect these properties, will
improve design of novel albumin-based therapeutics with tailored
pharmacokinetics.
We have previously reported that the C-terminal domain
(DIII) of HSA contains the main binding site for hFcRn, and that
DI modulates the interaction30,33,56. In addition, we have shown
that deletion of the last α-helix of HSA reduces binding30,34.
More than 70 genetic variants of HSA have been identified57.
Here, we studied the Bazzano, Catania, Rugby Park, and Venezia
variants, which have amino acid substitutions and truncations in
the C-terminal end35–38. The variants were first identified during
routine clinical electrophoresis run on serum from heterozygous
carriers of one normal and one mutated albumin gene, in which
the variants are present at lower levels than the normal
protein35,37,38. Thus, they are secreted into the circulation, but it
is not known whether the genetic modifications affect the rate of
expression and secretion by liver cells. Furthermore, CD analysis
has demonstrated that the modifications in the C-terminal end
increase or decrease the overall α-helical content and thermal
stability58,59. In this study, we found that all four variants have
reduced binding affinity toward hFcRn. The weakest binding was
measured for Rugby Park, which is present at only 8% of the total
serum albumin, followed by Bazzano, Venezia, and Catania
representing 18%, 30%, and 30%, respectively35,37,38. Thus, the
FcRn-binding affinity of the variants correlate with their serum
level in heterozygous carries.
Furthermore, we demonstrate that a fully intact C-terminal end
of HSA is required for optimal binding to hFcRn, as removal of
the very last L585 residue resulted in more than fivefold weaker
affinity due to slower association and faster dissociation. HDX-
MS data support that differences in structural dynamics con-
tribute to reduced binding of the truncated variant, as deletion of
the leucine led to structural stabilization of three regions in DIII,
that have been reported to undergo large conformational changes
upon receptor binding (up to 19 Å in Cα–Cα distances)26. The
regions are located in or in close proximity to the interaction
interface in the co-crystal structure, and it has previously been
shown that targeted mutagenesis within these segments affect
receptor binding30,31. The data support that the presence of L585
causes a functionally important local destabilization and struc-
tural flexibility within DIII that is in favor of hFcRn binding.
From an evolutionary perspective, it is interesting that the C-
terminal leucine residue is not conserved, as it is only expressed
by human, chimpanzee, and orangutan. These are also the only
species that express albumin with a lysine instead of a proline in
position 573, which also has great influence on FcRn binding34,56.
Thus, in regard to binding affinity for hFcRn, the L585 residue
compensates for the lack of P573 in HSA. Since transporting
cargo is a main function, we speculate that different requirements
to albumin in this regard may have been the driving force
resulting in these species differences. Notably, as the leucine
influences the structural dynamics of DIII of HSA, it may well be
that its presence also affects the ligand binding properties of the
domain.
Interestingly, HSA that lacks the last C-terminal L585 residue
is present in the blood of healthy individuals, where it has been
measured to constitute 4–15% of the circulating albumin
pool39,40. In line with this, we found that ~3% of the total
albumin in plasma from a healthy control lacked the leucine. Like
the recombinant version, reduced binding to hFcRn was mea-
sured for L585X isolated from human plasma. As such, reduced
receptor binding provides an explanation for its short in vivo
half-life of 3.5 days. This was measured in a patient with acute
gallstone-induced pancreatitis, which is a condition where the
pancreatic duct that connects the pancreas to the small intestine
is blocked, leading to premature activation of pancreatic enzymes
that attack the pancreas51. At most, we found that 60% of the
total albumin was lacking L585, which is in line with previous
reports showing levels ranging from 17 to 93% in patients suf-
fering from pancreatic disease39,40. The truncated form is most
likely a result of exposure to CPA, which is synthesized by the
pancreas and normally released as a zymogen into the gut, but
found at elevated levels in plasma of individuals with
pancreatitis39,60,61. Similarly, a tenfold increase in the plasma
concentration of CPA, and a high percentage of circulating
L585X, has been measured in a severely traumatized patient62.
We speculate whether cleavage of L585 may be a way to promote
the clearance of albumin that carries metabolic waste products
that accumulate during acute disease. Interestingly, as the leucine
is not conserved, this would not necessarily apply to all species.
Future studies should address whether various ligands whose
binding induce conformational changes in HSA, could make the
protein more or less susceptible to enzymatic cleavage. Moreover,
as the basal level of the activated form of CPA in plasma is very
low60, this raises questions as to where and when HSA is cleaved
under normal conditions.
Our findings also have implications for HSA-based ther-
apeutics with a free C-terminal end, as exemplified here with a N-
terminal drug fusion approved for clinical use. Incubation of the
drug with CPA resulted in reduced binding to hFcRn due to loss
of L585. Thus, exposure to the enzyme in vivo will affect the
pharmacokinetics. Instead, genetic fusion of a drug of interest to
the C-terminal of HSA may be favorable to prevent enzymatic
cleavage, as long as the drug does not represent a substrate for
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0903-7 ARTICLE
COMMUNICATIONS BIOLOGY |           (2020) 3:181 | https://doi.org/10.1038/s42003-020-0903-7 | www.nature.com/commsbio 7
CPA itself or compromise hFcRn binding. We previously
demonstrated that genetic fusion of a small peptide or a single-
chain-variable fragment to both the N- or C-terminal end of HSA
slightly decreased binding to hFcRn63. Thus, it is crucial to
address whether or not a particular fusion of interest interferes
with binding to hFcRn, as it may vary depending on the nature of
the fused protein. Importantly, to secure long serum half-life,
engineered HSA variants with improved binding to hFcRn, such
as the K573P variant34, may be used to compensate for dimin-
ished receptor binding caused by C-terminal truncation or design.
Methods
Construction and production of HSA variants. A pcDNA3.1 vector containing
cDNA that encodes for full-length HSA has been described previously20, and
cDNA fragments encoding modified DIII sequence (K573P, L585X, Bazzano; (567)
ALPRRVKNLLLQVKLP(582), Catania; (580)KLP(582), Rugby Park; (572)
LLQFSSF(578), and Venezia; (572)PTMRIRE(578)) were sub-cloned into the
vector using the restriction sites BamHI and Xhol (GenScript, NJ, USA). The HSA
variants were produced by transient transfection of adherent HEK293E cells
(ATCC) using Polyethylenimine Max (Polysciences). To compare expression levels
of WT HSA and the genetic variants, HEK293E cells were seeded in six-well plates
and grown to 95–100% confluency before transfection. Growth medium was
harvested and replaced on days 1, 2, 4, and 6 post transfection, and the levels of
secreted protein were quantified using a two-way anti-HSA ELISA described below.
For production of larger protein quantities, HEK293E cells were grown in T175
flasks and transfected at 95–100% confluency. Growth medium was harvested and
replaced every second day for up to 2 weeks post transfection, before the HSA
variants were purified from collected media using CaptureSelect HSA-affinity
matrix (Life technologies) packed in a 5 ml column (Atoll). The column was pre-
equilibrated with 1× PBS/0.05% sodium azide, before the supernatant was applied
at a flow rate of 1–2 ml/min. The column was washed with 100 ml 1× PBS/0.05%
sodium azide, before the bound protein was eluted with 50 ml 0.1 M Glycine-HCl
(pH 3.0) and neutralized with 1M Tris-HCl (pH 8.0). The collected protein was
up-concentrated and buffer-exchanged to 1× PBS using Amicon Ultra-15 30 K
columns (Millipore). Size-exclusion chromatography was performed using a
Superdex 200 increase 10/300 GL column (GE Healthcare). The monomeric
fraction was collected and up-concentrated using Amicon Ultra-0.5 30 K columns
(Millipore). Protein concentrations were determined using a DS-11 spectro-
photometer (DeNovix). Each HSA variant (2 μg) was mixed with LDS sample
buffer (Novex) and distilled H2O. The samples were loaded onto a 12% Bis-Tris
NuPAGE SDS-PAGE gel in parallel with SpectraTM Multicolor Broad Range
Protein Ladder (Thermo Fisher), and separated at 200 V for 22 min in MES buffer,
followed by staining with Coomassie Brilliant Blue (Bio-Rad).
Production of recombinant hFcRn. A vector containing cDNA that encodes for
the three ectodomains (α1–α3) of the hFcRn HC genetically fused to the Schisto-
soma japonicum glutathione S-transferase (GST), and the human β2m subunit was
used64. Soluble GST-tagged hFcRn was expressed by transient transfected
HEK293E cells as described above, and purified using a GSTrap FF column (GE
Healthcare). Briefly, the column was pre-equilibrated with 1× PBS/0.05% sodium
azide, before the supernatant was applied at a flow rate of 1–2 ml/min. The column
was washed with 100 ml 1× PBS/0.05% sodium azide, before bound receptor was
eluted with 50 ml 10 mM reduced glutathione (Sigma-Aldrich) diluted in 50 mM
Tris-HCl (pH 8.0). The collected receptor was up-concentrated and buffer-
exchanged to 1× PBS using Amicon Ultra-15 10 K columns (Millipore).
For production of soluble His-tagged hFcRn, a Baculovirus expression vector
system was used, as described previously65. The viral stock encoding His-tagged
hFcRn was a kind gift from Dr. Sally Ward (University of Texas, Southwestern
Medical Center, Dallas, TX). Briefly, the vector contains cDNA that encodes for the
three ectodomains (α1–α3) of the hFcRn HC followed by six histidines, and the
human β2m subunit. High Five cells (Thermo Fisher Scientific) were cultured in
Express FIVE SFM medium supplemented with 10 mM L-glutamine and 1%
antibiotic-antimyotic (Thermo Fisher Scientific). The cells were cultured in
suspension at a density of 1 × 106 cells/ml at 27 °C with shaking at 160 rpm, and on
the day of infection, 1 ml of the viral stock was added per 500 ml of cell culture.
Post infection, the cells were incubated at 23.5 °C with shaking at 160 rpm for 72 h,
followed by centrifugation at 3500 rpm and 4 °C for 40 min. The supernatant was
filtrated through a 0.2-μm filter unit (Millipore), and 0.05% sodium azide was
added prior to storage at 4 °C. His-tagged hFcRn was purified using a HisTrap HP
column (GE Healthcare) supplied with Ni2+ ions as previously described29. Briefly,
the supernatant was adjusted to pH 7.2 by adding 1× PBS/0.05% sodium azide (pH
10.9). The column was pre-equilibrated with 1× PBS/0.05% sodium azide, before
the supernatant was applied at a flow rate of 5 ml/min. The column was washed
with 150 ml 1× PBS/0.05% sodium azide and 50 ml 25 mM imidazole/1× PBS (pH
7.3), before bound receptor was eluted with 50 ml 250 mM imidazole/ 1× PBS (pH
7.4). The collected receptor was up-concentrated and buffer-exchanged to 1× PBS
using Amicon Ultra-15 10 K columns (Millipore). Size-exclusion chromatography
was performed using a HiLoad 26/600 Superdex 200 prep grade column (GE
Healthcare) coupled to an ÄKTA FPLC instrument (GE Healthcare). The
monomeric fraction was collected and up-concentrated using Amicon Ultra-15 10
K columns (Milipore).
CD spectroscopy. CD spectra were recorded using a Jasco J-810 spectro-
polarimeter (Jasco International). Measurements were performed on WT HSA and
L585X (150 μg/ml) in 10 mM PBS (pH 5.5) without NaCl at 20 °C using a quartz
cuvette (Starna) with a path length of 0.1 cm. Each sample was scanned five times
at 20 nm/min (bandwidth of 1 nm, response time of 1 s) with wavelength range set
to 190–260 nm. The data were averaged, and the spectrum of a sample-free control
was subtracted.
hFcRn-HSA binding ELISA. A human IgG1 mutant (M252Y/S254T/T256E/
H433K/N434F) with specificity for 4-hydroxy-3-iodo-5-nitrophenylacetic acid66 (8
µg/ml) diluted in PBS (pH 7.4) was added to 96-well plates (Costar) and incubated
overnight at 4 °C. The wells were blocked with PBS containing 4% skimmed milk
(PBSM) (pH 7.4) for 1 h at room temperature (RT), and then washed three times
with PBS containing 0.005% Tween 20 (PBST) (pH 5.5). His-tagged hFcRn (10 µg/
ml) diluted in PBSTM (pH 5.5) were added to the wells and incubated for 1 h at
RT. HSA variants (15 μg/ml or twofold serial dilutions starting from 10 μg/ml)
diluted in PBSTM (pH 5.5) was added to the wells in duplicates and incubated for
1 h at RT. Horseradish peroxidase-conjugated monoclonal mouse anti-HSA anti-
body (1:5000) (Abcam) or alkaline phosphatase-conjugated polyclonal goat anti-
HSA antibody (1:3000) (Bethyl Laboratories, Inc.) diluted in PBSTM (pH 5.5) were
added to the wells and incubated for 1 h at RT. The wells were washed three times
with PBST (pH 5.5) after incubation of each layer. The wells were developed with
tetramethylbenzidine substrate (Calbiochem) or p-nitropenyl-phosphate substrate
(10 μg/ml) (Sigma-Aldrich) diluted in diethanolamine buffer. The absorbance was
measured at 620 nm or 405 nm using the Sunrise spectrophotometer (TECAN).
SPR. SPR was performed using Biacore 3000 or T200 (GE Healthcare). Following
the description provided by the manufacturer, CM5 sensor chips were coupled with
GST-tagged hFcRn (~2000 RU) or HSA variants (~200–500 RU) using amine-
coupling chemistry. Briefly, coupling was performed by injecting the receptor (10
μg/ml) or HSA (6–10 μg/ml) in 10 mM sodium acetate, pH 4.5 (GE Healthcare).
For affinity and kinetic measurements, twofold serial dilutions of monomeric His-
tagged hFcRn (0, 0.625, 1.25, 2.5, 5, 10, 20, 40, and 80 μM or 0, 0.0625, 0.125, 0.25,
0.5, 1, 2, 4, 8, 16, and 32 μM) were prepared in duplicates and injected over
immobilized HSA with a flow rate of 10 or 40 μl/min at 25 °C. Relative binding of
serum-derived HSA (WT HSA and L585X) was measured by injecting equal
amounts (1 μM) over immobilized hFcRn at a flow rate of 50 μl/min and tem-
perature of 25 °C. Phosphate buffer (67 mM phosphate buffer, 0.15 M NaCl, 0.05%
Tween 20) at pH 5.5 or pH 7.4 was used as running and dilution buffer, while HBS-
P buffer (0.01 M HEPES, 0.15 M NaCl, 0.005% surfactant P20) at pH 7.4 was used
for regeneration of the flow cells. All binding curves were zero adjusted, and the
reference cell value was subtracted. Binding kinetics and affinity values were esti-
mated using the Langmuir 1:1 ligand binding model or an equilibrium (Req)
binding model provided by the BIAevaluation 4.1 software or Biacore T200 Eva-
luation Software, version 3.0.
HDX-MS. All reagents were purchased from Sigma-Aldrich in analytical grade,
except for the immobilized pepsin beads (Thermo Scientific). The exchange reac-
tion was initiated by diluting HSA variants (20 pmol) 1:9 with 99% D2O (111.2 mM
Na2HPO4, 44 mM citric acid, pDread= 5.530) at 25 °C. After 15 s, 1 min, 10 min,
60 min, 480 min, and 2960 min, the exchange reaction was quenched by addition of
ice-cold quench buffer (0.8 M TCEP in 2M glycine, pH= 2.305) in a 1:1 rela-
tionship, thereby decreasing the pHread to 2.422. The quenched samples were
immediately frozen to 80 °C until analysis. “Maximally-labeled” control samples
were prepared by incubating samples for 2 days at 25 °C in presence of deuterated
guanidine hydrochloride (6 M), where after the samples were treated as described
above. All time points and the “maximally-labeled” samples were performed in
triplicate except the 2960 min sample, which was only analyzed a single time.
Incorporation of deuterium was examined as previously described67. The
quenched protein samples were defrosted and loaded onto a refrigerated reverse-
phase UPLC-HDX system (Waters Inc.) cooled to 0 °C. The UPLC-HDX system
was equipped with a self-packed pepsin column with an internal volume of 60 µl,
which was kept externally to allow rapid online digestion of deuterated protein
samples at 20 °C. The generated peptic peptides were captured on a C18 trap
column (ACQUITY UPLC BEH C18 1.7 µm VanGuard column, Waters Inc.) and
desalted for 3 min at 200 µL/min with 0.23% formic acid in water. After desalting,
the flow path of the system was configured to allow the peptides to be eluted onto a
C18 analytical column (ACQUITY UPLC BEH C18 1.7 µm, 1 × 100 mm column,
Waters Inc.). Here, the peptic peptides were separated by short gradient (7 min)
reversed-phase chromatography (solvent A, 0.23% formic acid in water; solvent B,
0.23% formic acid in acetonitrile) and ionized (into the gas-phase) by positive
electrospray ionization into a hybrid Q-TOF mass spectrometer (Synapt G2-Si,
Waters Inc.). Prior to mass analysis, peptide ions were separated according to their
ion mobility. Identification of peptides was performed on non-deuterated and fully
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reduced samples by tandem MS using both data-dependent and data-independent
(MSe) acquisition methods.
Lock mass correction with Glu1-fibrinopeptide B was applied to all recorded
spectra. To perform peptide identifications, the data were analyzed in PLGS 3.0,
which correlate precursor- and fragment ions to a local database containing the
sequence of WT HSA, pepsin, and randomized sequences of these two proteins as
well. To determine the deuterium uptake for each peptide, the HDX-MS data were
analyzed using the software DynamX 3.0 (Waters Inc.). To allow access to the HDX
data of this study, the HDX Data Summary Table (Supplementary Table 2) and the
HDX Data Table (Supplementary Data 1) are included in the Supporting
Information according to the community-based recommendations68.
HERA. In total, 7.5 × 105 HMEC1 cells stably expressing HA-hFcRn-EGFP69 were
seeded into 24-well plates per well (Costar) and cultured for 1 day in growth
medium. The cells were washed twice and starved for 1 h in Hank’s balanced salt
solution (HBSS) (Life Technologies). WT HSA or L585X (1000 nM) diluted in 250
μl HBSS (pH 7.4) were added per well and incubated for 4 h. The medium was
removed, and the cells were washed five times with ice-cold HBSS (pH 7.4).
Growth medium supplemented with MEM nonessential amino acids (Thermo
Fisher) was added and collected after 4 h. To quantify the amount of HSA in the
samples, a two-way anti-HSA ELISA was used as described below.
Mouse studies. Two hFcRn transgenic mouse strains were used in the study:
Hemizygous Tg32 mice (B6.Cg-Fcgrt tm1Dcr Tg(FCGRT)32Dcr/ DcrJ; The Jackson
Laboratory, Bar Harbor, ME) and homozygous Tg32-Alb−/− albumin deficient
mice (B6.Cg-Albem12Mvw Fcgrttm1Dcr Tg(FCGRT)32Dcr/Mvw; The Jackson
Laboratory). Tg32-Alb−/− mice (male, 11–16 weeks, 20–25 g, four mice/group)
received WT HSA or L585X (4 mg/kg) in 20 ml/kg 1× PBS by intraperitoneal
injection, and blood (25 μl) was drawn from the retro-orbital sinus at 1, 8, 14, 20,
30, 45, and 58 days post injection. Tg32 mice (male, 7–8 weeks, 20–25 g, five mice/
group) received WT HSA or L585X (2 mg/kg) in 10 ml/kg 1× PBS by intravenous
injection, and blood (25 μl) was drawn from the retro-orbital sinus at 1, 2, 3, 5, 7,
and 10 days post injection. The blood samples were mixed with 1 μl 1% K3-EDTA
and maintained on ice until centrifugation at 17,000×g for 5 min at 4 °C. Plasma
was isolated and diluted 1:10 in 50% glycerol/PBS solution and stored at −20 °C.
The animal studies were carried out at The Jackson Laboratory (Tg32 study by JAX
Service, Bar Harbor, ME), and were performed in accordance with guidelines and
regulations approved by the Animal Care and Use Committee at The Jackson
Laboratory. To quantify the amount of HSA in plasma (diluted 1:200-1:400 in
PBSTM), a two-way anti-HSA ELISA was used as described below. The plasma
concentration was presented as percentage remaining in the circulation at different
time points post injection compared to the concentration on day 1 (100%). The β-
phase half-life was calculated using the formula: t1/2= log 0.5/(log Ae/A0) × t,
where t1/2 is the half-life of the HSA variant evaluated, Ae is the amount of HSA
remaining, A0 is the amount of HSA on day 1, and t is the elapsed time.
Two-way anti-HSA ELISA. Polyclonal goat anti-HSA (1.0 μg/ml) (Sigma-Aldrich)
or monoclonal mouse anti-HSA (1.0 μg/ml) (Abcam) diluted in PBS were added to
96-well ELISA plates (Costar) and incubated overnight at 4 °C. The wells were
blocked with PBSM overnight at 4 °C, and then washed three times with PBST.
Serial dilutions of HSA (500.0–0.2 ng/ml) in PBSTM were applied in parallel with
collected growth medium, HERA samples or plasma, followed by 1 h incubation at
RT. The wells were washed three times with PBST, before bound HSA was detected
using alkaline phosphatase-conjugated polyclonal anti-HSA antibody from goat
(1:3000) (Bethyl Laboratories, Inc.). The wells were washed three times with PBST
and then developed with p-nitropenyl-phosphate substrate (10 μg/ml) (Sigma-
Aldrich) diluted in diethanolamine buffer. The absorbance was measured at 405
nm using the Sunrise spectrophotometer (TECAN).
ESI-MS and isolation of L585X from human plasma. The patient included in the
study experienced a single acute event of gallstone induced pancreatitis. Blood
samples were taken upon hospital admission and then 2.2, 32.9, 35, 57.4, and 104.3
h after admission. Pancreatic amylase activity and lipase activity were measured on
an Abbott c8000/c16000 analyzer (Abbott Laboratories) according to the manu-
facturer’s protocol using a reference range of 8–53 U/L and 10–70 U/L, respectively.
The total serum albumin concentrations were determined by bromocresol green
binding method (normal range 35–50 g/L). To quantify the level of L585X in the
blood, 10 µl of plasma was incubated for 2 h at 37 °C with 0.5 µl 150 mM dithio-
threitol. Then, 1.5 µl of the mixture were separated by reverse-phase high-perfor-
mance liquid chromatography on a Phemomenix C-4 column (25 × 0.46 cm). The
HSA peak crest was collected, and 20 µl directly injected into the electrospray
source of a Platform II mass spectrometer at a flow rate of 10 µl/min. Data were
acquired and processed using MassLinks, and deconvoluted using Max-Ent soft-
ware. The half-life of L585X was calculated using the formula: t1/2= log 0.5/(log
Ae/A0) × t, where t1/2 is the half-life of L585X, Ae is the percentage of L585X in the
blood, A0 is the percentage of L585X in the blood 2.2 h after hospital admission,
and t is the elapsed time since the 2.2 h blood sample.
HSA was isolated from a healthy control and from a patient with alcohol
induced pancreatitis having 100% L585X, using DEAE Sephadex chromatography
employed 16 mM sodium acetate buffers with a pH gradient from pH 5.2 to 4.439.
The study was carried out in accordance with the Declaration of Helsinki principles
and the Canterbury Health Laboratories guidelines on clinical samples. The
patients gave written informed consent.
CPA digestion. HSA WT, K573P or Tanzeum® (15 μM) in 1× PBS were incubated
with human pancreatic CPA (30 µg/ml) (Elastin Products Company, Inc.) for 5 h at
37 °C with shaking.
LC–MS/MS. LC–MS/MS was used to analyze HSA samples that had been incu-
bated with or without CPA. Each sample (3 µg) was mixed with 50 mM NH4HCO3
(pH 7.8) to a volume of 18 µl. For protein reduction, 2 µl 100 mM dithiothreitol
was added and incubated for 30 min at 56 °C. For alkylation, 5 µl 55 mM iodoa-
cetamide was added and incubated in the dark for 30 min at RT. For protein
digestion, trypsin (0.5 µg) was added to each sample and incubated in a wet
chamber overnight at 37 °C. The samples were subsequently purified on C18 micro
columns: three discs were assembled in a 200 µl pipette tip and activated by 50 µl
MeOH followed by 50 µl ACN. The discs were equilibrated twice by 80 µl 0.1%
TFA before the samples were added. The discs were washed twice by 80 µl 0.1% FA
before the samples were eluted by 80 µl 80% ACN/0.1% FA. Then, the samples
were centrifuged in a speed vacuum concentrator to remove ACN, and the volume
was adjusted to 7 µl using 0.1% FA. Thus, the samples were diluted seven times,
and then stored at −20 °C until analysis. The samples were analyzed using an
EASY-LC coupled to Q Exactive Quadrupole-Orbitrap mass spectrometer (Thermo
Fisher) with the EASY Spray PepMap®RSLC column (C18, 2 µl, 100 Å, 75 µm × 25
cm) and column temperature at 60 °C. A 60min gradient and injections of 3 µl
were used.
MS raw files were submitted to MaxQuant software (version 1.6.1.0) for protein
identification and rough quantification. Searches were done against the sequences
of WT HSA and L585X. Parameters were set as follow: carbamidomethylation as
fixed modification, and protein N-acetylation and methionine oxidation as variable
modifications. First search error window of 20 ppm and mains search error of 4.5
ppm. Trypsin with two allowed miscleavages was used. Quantification was done on
the peptide level by comparing the intensity of the C-terminal peptide lacking L585
against the intensity of the corresponding WT peptide within the same sample,
without correlating for possible differences in ionization efficiency of the single
peptides.
Sequence and structural analysis. The albumin sequences of human
(AAA98797), orangutan (NP_001127106.2), chimpanzee (XP_517233.3), macaque
(NP_001182578.1), panda (XM_002928492.3), elephant (AAT90502.1), horse
(NP_001075972.1), donkey (AAV28861), cattle (AAA51411), goat (ACF10391),
sheep (NP_001009376), pig (AAA30988.1), dog (CAB64867.1), cat (CAA59279.1),
rabbit (NP_001075813), opossum (XM_001364821.2), hamster (ABR68005.1),
guinea pig (AAQ20088.1), rat (AAH85359.1), and mouse (AAH49971) were
downloaded from the National Center for Biotechnology Information. The align-
ments were made using Clustalω software.
The coordinates of the crystal structure of HSA (PDB ID 1AO6)3 and of HSA in
complex with hFcRn (PDB ID 4N0F)26 were used and inspected using the PyMOL
software (Schrodinger Inc.).
Statistics and reproducibility. Statistical analysis of the data obtained by HDX-
MS was performed using Excel software (Microsoft). HDX was performed with
triplicates of each albumin variant for all time points, except for the 2960 min
sample where n= 1. For data points performed in triplicate, the comparative
analyses were performed with either a homoscedastic or a heteroscedastic Student’s
t test, depending on the equality of the variances of the compared data points. The
equality of the variances was determined by an F test with the significance level set
to 0.05. A peptide was only considered to have a significant difference in HDX if
one of its data points met the following two criteria70: (1) a significant difference in
deuterium uptake (p < 0.05), and (2) the absolute difference in deuterium uptake
should be larger than two times the pooled standard deviation (|ΔD | > 2 ×
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
SD2wt þ SD2L585X
p
= 0.13D) (Supplementary Fig. 7). For the last (2960 min) time
point, for which replicate data were not obtained, statistical significance was
determined if the change exceeded a 99% confidence limit (±0.26 D) following the
method described by Houde et al. and Arora et al.71,72. This 99% confidence limit
was estimated from 385 single measurements of standard deviations from each
protein state.
Statistical analysis of the data obtained by HERA and half-life measurements in
mice was performed using GraphPad Prism 8 (GraphPad Software Inc.). The
HERA experiment was performed three times, where three wells for each albumin
variant was included each time. Half-life measurements were performed once in
Tg32-Alb−/− mice and once in Tg32 mice, where four and five mice per albumin
variant were included, respectively. Statistical significance was assessed by an
unpaired Student’s t test (with 95% confidence level and a two-sided p < 0.05
defined as a significant difference).
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Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data that support the findings of this study are stored in excel file format and are
available from the corresponding author upon reasonable request. Source data
underlying graphs presented in the main figures are available in Supplementary Data 1
and 2.
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